The anti-CCL2 monoclonal antibody carlumab failed to inhibit tumor growth in early stage clinical trials in prostate cancer, since CCL2 levels increased just one week after the treatment through the induction of compensatory mechanisms [40]. This evidence concerns the gene CCL2 and neoplasm.